►►Submit your paper by clicking the ABOVE RED TAG "ONLINE SUBMISSION".
►►Very important notification on publication fee
Effective February 2019, Cancer Biology & Medicine, as an open access journal, will charge a reasonable publication fee of $1,500/¥10,000 for each accepted article (all article types). No fees will be charged for invited articles.
Cancer Biology & Medicine is a peer-reviewed open-access journal published by the China Anti-cancer Association (CACA), which is the leading professional society of oncology in China. Published quarterly, the journal provides innovative and significant information on the biological basis of cancer, cancer microenvironment, translational cancer research, and all aspects of clinical cancer research. The journal also publishes significant perspectives on indigenous cancer types in China. The scope covers the following topics:
● Cancer genetics
● Cancer and stem cell biology
● Molecular and clinical immunology
● Cancer prevention and epidemiology
● Cancer biomarkers
● Radiation oncology
● Oncology clinical trials
● Mechanisms of drug sensitivity and resistance
● Targeted therapy and immunotherapy
● Multidisciplinary treatment and personalized medicine
Author Benefits
● Easy submission via online system
● Efficient and professional peer review
● Rapid pre-print online publication
● No charge for publication and open access
● International visibility-All full texts are free in PubMed Central
Announcements
Publication of the 2nd issue in 2021 |
|
In this issue, contents of five reviews focus on application of nano-medicine in cancer theranostics, which refer to stimuli-responsive nanocarriers, nanotechnology-based theranostic systems, delivery vehicles related to vaccine development, Gold-based nanomaterials in brain cancer treatment, and nanotechnology in overcoming drug resistance. Meanwhile, circular RNA, as another important topic, is involved in reviews on its role in epithelial-mesenchymal transition and chemoresistance as well as its potential clinical values. Original researches also include some new discoveries on basic and clinical researches. For instance, results from the following 2 papers are full of novelty and practical value: “rBRCA mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees” and “The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma”. Except for the aforementioned contents, other summaries and researches are also highly recommended. We hope the issue will greatly benefit your research and clinical practice. Welcome to submit your work to Cancer Biology & Medicine. |
|
| Posted: 2021-05-14 | |
Publication of the 1st issue in 2021 |
|
Basic research on oncology is the main content of this issue. Epigenetics and updated immunotherapy targets for lymphoma, the roles of some molecules in development of lung cancer, as well as other contents including tumor microenvironment, DNA damage, response for cancer therapy and so on are included. A review discussing intermittent fasting induces an interesting topic. Another systematic review focuses cancer patients with COVID-19.Original clinical studies are also worthy of reading indeed, including biomarkers for diagnosis of hepatocellular carcinoma, relevant of systemic inflammation and BMI with survivals of upper digestive duct cancers, comparison of different treatment for bladder cancer etc. We hope the issue will greatly benefit your research and clinical practice. Welcome to submit your work to Cancer Biology & Medicine. |
|
| Posted: 2021-02-05 | |
| More Announcements... |
Vol 18 (2021): Online first articles
Table of Contents
Review
| The biological role of the CXCL12/CXCR4 axis in esophageal squamous cell carcinoma | |
| Xianxian Wu, et al. | 1-10 |
| Epithelial-mesenchymal transition-related circular RNAs in lung carcinoma | |
| Meina Jiang, et al. | 1-10 |
| Biological roles and potential clinical values of circular RNAs in gastrointestinal malignancies | |
| Xueping Tao, et al. | 1-21 |
| Biomaterial-based platforms for cancer stem cell enrichment and study | |
| Chunhua Luo, et al. | 1-12 |
| Stimuli-responsive nanocarriers for therapeutic applications in cancer | |
| Xubo Zhao, et al. | 1-17 |
| Circular RNAs: new biomarkers of chemoresistance in cancer | |
| Jiaqi Wang, et al. | 1-16 |
| Nanotechnology assisted photo- and sonodynamic therapy for overcoming drug resistance | |
| Rui Li, et al. | 1-13 |
| Recent progress of nanotechnology-based theranostic systems in cancer treatments | |
| Ying Xue, et al. | 1-16 |
Original Article
| LncRNA HIF1A-AS2 accelerates malignant phenotypes of renal carcinoma by modulating miR-30a-5p/SOX4 axis as a ceRNA | |
| Mingwei Chen, et al. | 1-18 |
| NEDD9 promotes cancer stemness by recruiting myeloidderived suppressor cells via CXCL8 in esophageal squamous cell carcinoma | |
| Dongli Yue,et al. | 1-18 |
| BRCA mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees | |
| Laura Cortesi, et al. | 1-7 |
| Raltitrexed as a synergistic hyperthermia chemotherapy drug screened in patient-derived colorectal cancer organoids | |
| Lisi Zeng, et al. | 1-31 |
| A nomogram-based immune-serum scoring system predicts overall survival in patients with lung adenocarcinoma | |
| Qiujuan Huang, et al. | 1-15 |
| Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER-2 negative metastatic breast cancer | |
| Nanlin Hu, et al. | 1-11 |
| Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases | |
| Zhen Zhou, et al | 1-12 |
| L1CAM overexpression promotes tumor progression through recruitment of regulatory T cells in esophageal carcinoma | |
| Xuan Zhao, et al. | 1-15 |
| Synergistic effects of AAGL and anti-PD-1 on hepatocellular carcinoma through lymphocyte recruitment to the liver | |
| Xiangdong Ye, et al. | 1-17 |
| CD13 inhibition augments DR4-induced tumor cell death in a p-ERK1/2-independent manner | |
| Jun Ni, et al. | 1-18 |
| Analysis of the HNF4A isoform-regulated transcriptome identifies CCL15 as a downstream target in gastric carcinogenesis | |
| Zhen Ni, et al. | 1-17 |
| Modified R-CODOX-M/IVAC chemotherapy regimens in Chinese patients with untreated sporadic Burkitt lymphoma | |
| Meiting Chen, et al. | 1-8 |
| SNORA23 inhibits HCC tumorigenesis by impairing the 2ʹ-O-ribose methylation level of 28S rRNA | |
| Zhiyong Liu, et al. | 1-16 |
| FGFR/RACK1 interacts with MDM2, promotes P53 degradation, and inhibits cell senescence in lung squamous cell carcinoma | |
| Tao Chen, et al. | 1-10 |
| Overexpressed NEDD8 as a potential therapeutic target in esophageal squamous cell carcinoma | |
| Jingrong Xian, et al. | 1-14 |
| Transcription factor-based gene therapy to treat glioblastoma through direct neuronal conversion | |
| Xin Wang, et al. | 1-15 |
| The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma | |
| Yan Song, et al. | 1-7 |
| Heat shock protein 90 promotes RNA helicase DDX5 accumulation and exacerbates hepatocellular carcinoma by inhibiting autophagy | |
| Ting Zhang, et al. | 1-12 |
| Three-dimensional collagen-based scaffold model to study the microenvironment and drug-resistance mechanisms of oropharyngeal squamous cell carcinomas | |
| Giacomo Miserocchi, et al. | 1-15 |
| VHH212 nanobody targeting the hypoxia-inducible factor 1α suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer in vivo | |
| Guangbo Kang, et al. | 1-16 |
| A novel recurrence-associated metabolic prognostic model for risk stratification and therapeutic response prediction in patients with stage I lung adenocarcinoma | |
| Chengming Liu, et al. | 1-16 |
| Drug repurposing for cancer treatment through global propagation with a greedy algorithm in a multilayer network | |
| Xi Cheng, et al. | 1-16 |
| Protein convertase subtilisin/Kexin type 9 inhibits hepatocellular carcinoma growth by interacting with GSTP1 and suppressing the JNK signaling pathway | |
| Mingyan He, et al. | 1-14 |
| sLex expression in invasive micropapillary breast carcinoma is associated with poor prognosis and can be combined with MUC1/EMA as a supplementary diagnostic indicator | |
| Yawen Song, et al. | 1-13 |
| The commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasms | |
| Huihui Yin, et al. | 1-13 |
| Epstein-Barr virus DNA loads in the peripheral blood cells predict the survival of locoregionally-advanced nasopharyngeal carcinoma patients | |
| Yongqiao He, et al. | 1-12 |
| Evaluation of 30 DNA damage response and 6 mismatch repair gene mutations as biomarkers for immunotherapy outcomes across multiple solid tumor types | |
| Zhe Gong, et al. | 1-12 |
| Complement C3a activates osteoclasts by regulating the PI3K/PDK1/SGK3 pathway in patients with multiple myeloma | |
| Fengjuan Jiang, et al. | 1-13 |
| CUL4B facilitates HBV replication by promoting HBx stabilization | |
| Haixia Shan, et al. | 1-12 |
OUR FRIENDS
